Back to Journals » Research and Reports in Urology » Volume 6

Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer

Authors Zobniw C, Causebrook A, Fong MK

Received 8 April 2014

Accepted for publication 10 June 2014

Published 5 August 2014 Volume 2014:6 Pages 97—105

DOI https://doi.org/10.2147/RRU.S29003

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2


Chrystia M Zobniw,1 Alanna Causebrook,2 Mei Ka Fong1

1Department of Pharmacy, Roswell Park Cancer Institute, Buffalo, NY, USA; 2School of Pharmacy, Lake Erie College of Osteopathic Medicine, Erie, PA, USA

Abstract: Prostate cancer remains the most common type of cancer among men in the United States. Treatment for metastatic prostate cancer has improved significantly over the years with more and more agents improving overall survival. This review will address the pathophysiology of prostate cancer followed by the mechanism of action and the pharmacokinetic properties of abiraterone. The review will also discuss the role of abiraterone in the treatment of metastatic castrate-resistant prostate cancer.

Keywords: glucocorticoid receptor, CYP17, pipeline, enzalutamide, sipuleucel-T, drug resistance, radium-223 dichloride

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]